Biohaven Ltd. (NYSE:BHVN) Shares Acquired by Inspire Investing LLC

Inspire Investing LLC lifted its holdings in Biohaven Ltd. (NYSE:BHVN) by 57.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,150 shares of the company’s stock after purchasing an additional 3,706 shares during the period. Inspire Investing LLC’s holdings in Biohaven were worth $352,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its stake in Biohaven by 280.5% during the 1st quarter. Vanguard Group Inc. now owns 6,308,853 shares of the company’s stock worth $345,031,000 after buying an additional 4,650,702 shares in the last quarter. Darwin Global Management Ltd. acquired a new stake in shares of Biohaven in the first quarter valued at $80,776,000. Point72 Asset Management L.P. increased its stake in Biohaven by 142.2% during the fourth quarter. Point72 Asset Management L.P. now owns 2,483,567 shares of the company’s stock worth $106,297,000 after purchasing an additional 1,458,072 shares during the period. Bellevue Group AG purchased a new stake in Biohaven during the 4th quarter worth approximately $46,010,000. Finally, Perceptive Advisors LLC increased its position in shares of Biohaven by 129.4% during the fourth quarter. Perceptive Advisors LLC now owns 1,725,047 shares of the company’s stock worth $73,832,000 after acquiring an additional 973,227 shares during the period. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Biohaven

In other news, Director John W. Childs purchased 28,400 shares of the firm’s stock in a transaction on Thursday, July 18th. The shares were bought at an average cost of $35.67 per share, with a total value of $1,013,028.00. Following the purchase, the director now directly owns 2,339,741 shares of the company’s stock, valued at $83,458,561.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 16.00% of the stock is currently owned by corporate insiders.

Biohaven Price Performance

Shares of BHVN opened at $40.39 on Monday. Biohaven Ltd. has a 1-year low of $16.45 and a 1-year high of $62.21. The stock has a market cap of $3.57 billion, a price-to-earnings ratio of -5.91 and a beta of 1.30. The firm has a 50 day simple moving average of $38.35 and a 200-day simple moving average of $40.83.

Biohaven (NYSE:BHVN) last released its quarterly earnings results on Thursday, August 8th. The company reported ($3.64) earnings per share for the quarter, missing the consensus estimate of ($1.72) by ($1.92). On average, equities analysts expect that Biohaven Ltd. will post -8.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on BHVN. Morgan Stanley began coverage on shares of Biohaven in a research note on Wednesday, July 24th. They set an “overweight” rating and a $58.00 target price on the stock. Sanford C. Bernstein initiated coverage on Biohaven in a report on Wednesday, September 4th. They issued an “outperform” rating and a $55.00 target price for the company. Jefferies Financial Group started coverage on shares of Biohaven in a research note on Monday, September 16th. They set a “buy” rating and a $57.00 price target for the company. UBS Group lowered their target price on Biohaven from $55.00 to $54.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. Finally, William Blair upgraded shares of Biohaven to a “strong-buy” rating in a research note on Friday, August 30th. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Biohaven currently has a consensus rating of “Buy” and an average price target of $54.70.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.